Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | Molecular testing in the UK

John Bridgewater • 29 Jul 2021
Bile Duct Cancer Gastrointestinal Cancer Pemigatinib

John Bridgewater, BA, MBBS, MRCP, PhD, University College London Hospitals NHS Foundation Trust, London, UK, discusses advances and logisitics of molecular testing in the UK. He discusses the molecular testing required for patients with cholangiocarcinoma for fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement, prior to treatment with pemigatinib. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Disclosures

Prof. Bridgewater reports advisory capacity to Incyte.

More from John Bridgewater

2:42
Current and future treatment options for cholangiocarcinoma
John Bridgewater • 29 Jul 2021

Related Videos

1:53
Important pathophysiological determinants of elevated cirDNA post-surgery
Alain Thierry • 9 Apr 2024
0:47
Emerging molecular drivers and biomarker targets in gastroesophageal cancers
Tatsuhiro Shibata • 9 Apr 2024
0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals